Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CpG 7909 adjuvant for pneumococcal vaccination in HIV-infected adults
NCT00562939Phase 2Completed
- Sponsor
- Aarhus University
- Start
- Jan 2008
- Primary completion
- Jan 2009
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of agatolimod in pneumococcal disease, sponsored by Aarhus University. Primary endpoint: Numbers of vaccine high responders at 270 days. Started Jan 2008; status: completed.
02
Drugs
agatolimod
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT00562939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00562939.